BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded up 32.8% during mid-day trading on Thursday . The company traded as high as $3.75 and last traded at $3.56, with a volume of 806,806 shares changing hands. The stock had previously closed at $2.68.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a report on Wednesday, May 11th.

The stock’s 50 day moving average price is $2.48 and its 200 day moving average price is $2.42. The stock’s market capitalization is $55.78 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. On average, equities research analysts expect that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.